---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-040919"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:04:24.148381+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roivant prices $150M primary/secondary offering at $5.00 per share

## Summary
- Company sold 20M shares for ~$100M gross; selling shareholders sold 10M for ~$50M; $5.00/share.
- Underwriter granted 30-day option to purchase up to $22.5M additional common shares.
- Roivant expects cash position to fund operations into H2 2025; proceeds not received from selling shareholders.
- Offering closed on Nov 10, 2022; sole bookrunner Cantor Fitzgerald.
- Registration statement effective Oct 3, 2022; prospectus supplement filed Nov 8.

## SEC filing metadata
- accession: 0001140361-22-040919
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/0001140361-22-040919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/ny20005775x4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-040919
- JSON: https://secwatch.observer/filing/0001140361-22-040919.json
- Plain text: https://secwatch.observer/filing/0001140361-22-040919.txt

## Key facts
- Material Agreements
  Roivant Sciences Ltd. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at $150 million (effective 2022-11-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: $150 million
  - Effective: 2022-11-08
  source text: On November 8, 2022, Roivant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, and the selling shareholders named therein (the “Selling Shareholders”) relating to the issuance and sale in an underwritten offering (the “Offering”) of 30,000,000 (the “Shares”) of the Company’s common shares, par value $0.0000000341740141 per share, at an offering price of $5.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/0001140361-22-040919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.